Combating multidrug-resistant pathogens with host-directed nonantibiotic therapeutics

Keyphrases

• % Protection 75%
• Acinetobacter Baumannii (A. baumannii) 25%
• Age of Infection 50%
• Amoxapine 75%
• Antibiotic-free 100%
• Antidepressants 25%
• Antipsychotics 25%
• Approved Drugs 25%
• Baumannii 25%
• Bubonic Plague 25%
• Clostridium Difficile Infection 25%
• Cytotoxicity 25%
• Doxapram 50%
• Drug Repurposing 25%
• Host-directed 100%
• In Vitro Cytotoxicity 25%
• Inhibit Bacteria 25%
• Intracellular Survival 25%
• Klebsiella Pneumoniae (K. pneumoniae) 50%
• Levofloxacin 25%
• Macrophage Cytotoxicity 50%
• Macrophages 25%
• Multidrug-resistant Pathogens 100%
• Multiple Antibiotic Resistance 25%
• Murine Macrophages 50%
• New Therapeutics 25%
• Non-antibiotic Pharmaceuticals 50%
• Pneumonic Plague 75%
• Post-infection 100%
• Public Health Risk 25%
• Resistant Strains 25%
• Respiratory Infection 25%
• Stimulants 25%
• Therapeutic Potential 25%
• Trifluoperazine 50%
• Vancomycin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Acinetobacter Baumannii 33%
• Amoxapine 100%
• Antidepressant 33%
• Antipsychotic 33%
• Bubonic Plague 33%
• Clostridium Difficile Infection 33%
• Cytotoxicity 100%
• Cytotoxicity Assay 33%
• Doxapram 66%
• Drug Repositioning 33%
• Infection 66%
• Infectious Agent 100%
• Klebsiella pneumoniae 33%
• Levofloxacin 33%
• Murine 33%
• Pneumonic Plague 100%
• Respiratory Stimulant Agent 33%
• Respiratory Tract Infection 33%
• Trifluoperazine 66%
• Vancomycin 33%

Immunology and Microbiology

• Acinetobacter Baumannii 25%
• Breathing 25%
• Cytotoxicity 100%
• Exhalation 25%
• Infectious Agent 100%
• Klebsiella pneumoniae 25%
• Macrophage 100%
• Murine 25%
• Peptoclostridium difficile 25%